Targeted Genetics Patents
Targeted Genetics has filed 13 patents.
Molecular biology, Genetics, Stylidium, Biotechnology, Gene expression
Molecular biology, Genetics, Stylidium, Biotechnology, Gene expression
Latest Targeted Genetics News
Dec 31, 2015
XconomySeattle — H. Stewart Parker is the former CEO of Seattle’s Targeted Genetics, a pioneering gene therapy company that fizzled out after nearly 20 years but helped pave the way for a new generation of companies, such as Bluebird Bio and Spark Therapeutics, that are moving gene therapies through the clinic. Parker spent time at the head of the Infectious Disease Research Institute, also in Seattle, and is now a director of several biotechs including the gene editing specialists Sangamo Biosciences. We caught up with her to ask a few end of year questions. (Answers have been edited for length and clarity. ) Xconomy: What will happen if a Republican is elected president in 2016 and the Affordable Care Act is dismantled? Stewart Parker: The question is moot. The Republicans are so badly disorganized that Hillary Clinton has a clear path to the White House in 2016. X: Have you been sequenced? If yes, did you find anything interesting? If no, what would prompt you to do it? SP: I haven’t been sequenced. I think at this point the cost-benefit ratio is not there. From looking at my relatives and monitoring my health pretty closely, I think I would be better off spending the money on fresh healthy food, exercise, and optimizing my mental health by having fun with friends and enjoying activities I’m passionate about. X: The first gene therapy to gain approval in the West, Glybera, came from UniQure a couple years ago, in Europe. But the product has yet to launch, and UniQure apparently isn’t seeking approval for Glybera in the U.S. What’s your outlook on gene therapies being approved and widely used by 2020? SP: Having been an early pioneer in gene therapy (Targeted Genetics, 1992-2008), I believe strongly that gene therapy has a major role in the armamentarium of how we treat a number of diseases. Yes, it has taken a while, as did monoclonal antibodies. If you are including the area of gene editing in that question, as well, then I think there are a number of exciting opportunities focused on somatic cell transformation at this point. We need to proceed cautiously in the application of gene editing to non-somatic cells. X: Drug pricing will be a top issue in 2016. Will the noise actually lead to changes? SP: I think the sector would be wise to examine its practices and make changes prior to being forced to. The censure of Turing Pharmaceuticals, and even Valeant [Pharmaceuticals International], is an example. The sector looks ludicrous when it claims high prices are due to research costs while spending more on advertising than research. Maybe we should really think out of the box: How about limiting direct-to-consumer advertising? X: How do you make time to think these days? SP: I enjoy my work, but do find that getting away on a trout stream occasionally makes a huge difference in my outlook on life! Photo of Hat Creek, CA, courtesy of Sandip Bhattacharya via a Creative Commons license.
Targeted Genetics Frequently Asked Questions (FAQ)
When was Targeted Genetics founded?
Targeted Genetics was founded in 1989.
Where is Targeted Genetics's headquarters?
Targeted Genetics's headquarters is located at 1100 Olive Way, Seattle.
What is Targeted Genetics's latest funding round?
Targeted Genetics's latest funding round is PIPE - IV.
Who are the investors of Targeted Genetics?
Investors of Targeted Genetics include Heights Capital Management, Downsview Capital, OrbiMed Advisors, Merlin Biomed Group, Fort Mason Capital and 14 more.
Who are Targeted Genetics's competitors?
Competitors of Targeted Genetics include Dicerna Pharmaceuticals, MaxCyte, Panacea Pharmaceuticals, Blue Heron Biotech, Agrisoma BioSciences and 7 more.
Compare Targeted Genetics to Competitors
Cell Point is a biotechnology company, develops radiodiagnostic imaging and intracellular therapeutic agents, and delivery systems for the administration of local regional radio/chemotherapy.
Targeson is a biotechnology company that develops, manufactures, and markets ultrasound contrast agent technologies for pre-clinical molecular imaging in animal models. Targeson is also developing this technology for site-specific diagnosis and therapy in humans. The company has engineered a versatile microparticle platform that may be used as both a contrast agent and, in a slightly modified form, a drug or gene delivery agent. Targeson manufactures and sells the Targestarline of contrast agents for ultrasound-based molecular and functional imaging in animal models of disease. Targeson's agents can be readily targeted to the molecular signature of many diseases, and can be used to detect pathophysiology on the molecular level. The company's intellectual property aims to enable the agents to bind with high efficiency to the intended molecular targets. In addition, the company is investigating therapeutic technology for simultaneous imaging and delivery, which aims to enable the user to verify that the therapeutic compound has been delivered to the intended site.
OrphageniX is a drug development company aiming to develop therapeutics for genetic diseases using advancements in "Gene Editing" technologies. OrpageniX will focus on the low volume, high margin specialty pharmaceutical niche area of "Orphan Diseases" which are protected under the Orphan Drug Act (ODA). Per the company, the OrphageniX technology can be used for diagnostics and research tools. Gene Editing uses the cell's innate repair mechanisms to repair mutations that result in genetic diseases. According to OrphaageniX, it is similar to gene therapy but avoids the risks associated with a viral vector. It works like anti-sense and RNAi, but is more efficient and permanent within the repaired cell because it changes the gene itself and not the transient message. The company states that it has major collaborations with Yale Medical School, Albert Einstein Medical Center and the University of Washington.
Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.
Agrisoma BioSciences is a company focused on sustainable biofuel production in the renewable energy sector. The company's main product is Carinata, a non-food crop that is used to produce low greenhouse gas fuels and provide protein for animal nutrition. It is based in Gatineau, Quebec.
Vector Biolabs is a biotechnology company focused on developing robust gene delivery products, by using its technologies. The company's products are to be used in scientific research, target identification and drug development.